AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and OccupationsInformation ScienceHealth Care
Carcinoma, Pancreatic DuctalPancreatic NeoplasmsPancreatic DuctsCarcinomaCarcinoma, Ductal, BreastCarcinoma in SituCarcinoma, Squamous CellCarcinoma, HepatocellularAdenocarcinomaImmunohistochemistryPancreasCarcinoma, DuctalCarcinoma, Intraductal, NoninfiltratingCell Line, TumorPancreatitis, ChronicTumor Markers, BiologicalCarcinoma, PapillaryNeoplasm InvasivenessGene Expression Regulation, NeoplasticPancreatectomyPrognosisAdenocarcinoma, MucinousPancreatitisCarcinoma, Acinar CellBreast NeoplasmsLiver NeoplasmsPancreaticoduodenectomyGenes, rasNeoplasm StagingTissue Array AnalysisProto-Oncogene Proteins p21(ras)Precancerous ConditionsPancreatic JuiceCell ProliferationMice, NudeReverse Transcriptase Polymerase Chain ReactionCarcinoma, Basal CellTumor Cells, CulturedSmad4 ProteinAdenocarcinoma, PapillaryDisease ProgressionNeoplasm MetastasisLymphatic MetastasisNeoplasm ProteinsCyclic S-OxidesAcinar CellsRNA, MessengerCell Transformation, NeoplasticKaplan-Meier EstimateCarcinoma, Transitional CellDeoxycytidineGene Expression ProfilingCA-19-9 AntigenCarcinoma, BronchogenicNeoplasms, Multiple PrimarySurvival AnalysisCarcinoma, MedullaryNeoplasm TransplantationSignal TransductionCarcinoma, Adenoid CysticAmpulla of VaterSurvival RateCarcinoma, Small CellImmunoenzyme TechniquesMetaplasiaras ProteinsNeoplasm Recurrence, LocalAntineoplastic AgentsCarcinoma, LobularTumor Suppressor Protein p53Retrospective StudiesCarcinoma, NeuroendocrineApoptosisMutationTumor BurdenTreatment OutcomeEpithelial CellsXenograft Model Antitumor AssaysNasopharyngeal NeoplasmsDNA, NeoplasmThyroid NeoplasmsNeoplasm GradingBreastGenes, Tumor SuppressorOligonucleotide Array Sequence AnalysisCell Growth ProcessesCarcinoma, AdenosquamousMucin-1Lung NeoplasmsTumor MicroenvironmentRNA, Small InterferingKeratinsGene ExpressionCadherinsCarcinoma, MucoepidermoidBlotting, WesternCyclin-Dependent Kinase Inhibitor p16RNA, NeoplasmPancreatic Stellate CellsMice, Transgenic
Hepatocellular carcinomaColorectalTumorsNeoplasmsRenal cell carcCancerPrognosisIntraductalNeoplasiaSquamous cell carcAcinarLesionsNeuroendocrine tumorPatientsType of pancreaticPancreas2019InvasiveMetastasis2022AdenocarcinomasTherapiesCancersVitroCell proliferationCarcinogenesisComputed tomographyTissueResectionClinicalTumor suppressor
Hepatocellular carcinoma8
  • Locally advanced or metastatic hepatocellular carcinoma (HCC). (medscape.com)
  • Advanced hepatocellular carcinoma, pancreatic ductal adenocarcinoma (PDAC) and biliary tract cancer. (medscape.com)
  • Desmoplasia is a common hallmark of many malignancies including non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, and pancreatic ductal adenocarcinoma (PDAC). (nhri.org.tw)
  • The purpose of this study is to determine the safety and efficacy of belzutifan in combination with pembrolizumab and lenvatinib in multiple solid tumors including hepatocellular carcinoma (HCC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC), endometrial cancer (EC),and esophageal squamous cell carcinoma (ESCC). (merckclinicaltrials.com)
  • The Phase 2 part of this study is conducted to assess the objective response rate (ORR) of E7386 in combination with pembrolizumab (melanoma, colorectal cancer [CRC], hepatocellular carcinoma [HCC]) or of E7386 in combination with pembrolizumab plus lenvatinib (HCC) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. (ucbraid.org)
  • The purpose of this study is to evaluate the safety and effectiveness of triplet therapy of nivolumab, relatlimab and bevacizumab versus nivolumab and bevacizumab in participants with untreated advanced/metastatic hepatocellular carcinoma (HCC). (ucbraid.org)
  • The primary objectives of Cohort A Phase 1b are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent to participants with locally advanced or metastatic, and unresectable Hepatocellular Carcinoma (HCC) and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of TTI-101 as a single agent. (ucbraid.org)
  • Immunotherapy with dendritic cells and/or cytokine-induced killer cells for the treatment of hepatocellular carcinoma. (aetna.com)
Colorectal4
  • Digestive system tumors including esophageal cancer, colorectal cancer, gastric cancer, pancreatic cancer, hepatic cancer, cholangiocarcinoma, and gallbladder carcinoma are associated with significantly high mortality and morbidity rates [ 1 ]. (ijbs.com)
  • Similar to colorectal cancer, liver metastases of neuroendocrine cancer, gastrointestinal stromal tumor, and pancreatic cancer also determine patient prognosis to some extent. (cancertreatmentjournal.com)
  • In this review, we have summarized the therapeutic options for non-colorectal cancer liver metastases in neuroendocrine tumors, gastrointestinal stromal tumors, pancreatic cancer, kidney cancer, and breast cancer. (cancertreatmentjournal.com)
  • With CAF present in most tumor types including, for example, breast, pancreatic, colorectal, lung, liver and gastric, the development of FAP-targeted diagnostics holds great potential in oncology as well as other conditions including inflammation, fibrosis and arthritis 4 . (infrontfinance.com)
Tumors11
  • Pancreatic tumors are rare in children. (wikipedia.org)
  • The last type of exocrine tumors include pancreatic mucinous cystic neoplasms, which have fluid filled cavities. (wikipedia.org)
  • These types of tumors arise from hormone-producing cells in the pancreas and account for only 1-2% of all pancreatic tumors. (wikipedia.org)
  • For example, some of these pancreatic endocrine tumors release hormones such as insulin, gastrin and glucagon systemically. (wikipedia.org)
  • Pancreatic endocrine tumors are named after the type of hormone they release. (wikipedia.org)
  • The New Fully Automated System For Ki67 Evaluation in Pancreatic Neuroendocrine Tumors (PNETs). (unina.it)
  • Pancreatic neuroendocrine neoplasms (PanNENs) fall into two subclasses: the well-differentiated, low- to high-grade pancreatic neuroendocrine tumors (PanNETs), and the poorly-differentiated, high-grade pancreatic neuroendocrine carcinomas (PanNECs). (biomedcentral.com)
  • With this approach, PanNENs fall into two basic subtypes: well-differentiated pancreatic neuroendocrine tumors (PanNETs) and poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs) [ 4 ]. (biomedcentral.com)
  • For treatment of neuroendocrine cancers (i.e., carcinoid tumors and pancreatic endocrine tumors) involving the liver. (aetna.com)
  • In July 2022, I-Mab announced that the first patient in China has been treated with TJ-CD4B (also known as ABL111), a novel Claudin 18.2 x 4-1BB bispecific antibody, in a Phase 1 international multi-center clinical trial (IMCT) for patients with solid tumors, including gastric cancer, gastroesophageal junction carcinoma, esophageal adenocarcinoma, and pancreatic ductal carcinoma. (lucknownewsflash.in)
  • Improvement in the resectability of tumors requires detection of PDAC at an earlier stage. (medscape.com)
Neoplasms4
  • Pancreatic neuroendocrine neoplasms (PanNENs) have undergone several classification changes according to consensus guidelines [ 1 ]. (biomedcentral.com)
  • Background and Aim: Preoperative histological evaluation of pancreatic neoplasms is important for guiding the resection strategy and preventing postoperative adverse events. (elsevierpure.com)
  • Methods: This single-center prospective study included patients with pancreatic neoplasms between October 2018 and December 2019. (elsevierpure.com)
  • Thirteen individuals with FPC (6.1%) underwent surgical resection for a suspected PRL, but only four (1.9%) had high-risk lesions (ie, high-grade intraductal papillary mucinous neoplasms or grade 3 pancreatic intraepithelial neoplasms). (medscape.com)
Renal cell carc3
  • and a 3L non-clear cell renal cell carcinoma patient with SD. (tmcnet.com)
  • It is a category that includes many different kinds of cancer and is dominated by renal cell carcinoma. (cancer.gov)
  • Renal Cell Carcinoma (RCC) Classification - ccRCC, pRCC, and chRCC using New miRNA Biomarker Pane Ready-to-Use fully optimized SSNA miRNA In Situ Hybridization (ISH) Kit Renal cell carcinoma (RCC) consists of an array of morphologically and genetically distinct. (biogenex.com)
Cancer31
  • See also Ampullary Carcinoma , Pancreatic Cancer , Pancreatic Trauma , and Carcinoma of the Ampulla of Vater . (medscape.com)
  • Both the incidence and the death rates for pancreatic cancer are increasing. (medscape.com)
  • The initial manifestations of pancreatic cancer are often nonspecific, and consequently are often misinterpreted. (medscape.com)
  • Pancreatic cancer is notoriously difficult to diagnose in its early stages. (medscape.com)
  • Laboratory findings in patients with pancreatic cancer are usually nonspecific. (medscape.com)
  • Occasionally, the presence of pancreatic cancer is suggested by elevated liver transaminase, bilirubin, and alkaline phosphatase levels on testing performed for other purposes. (medscape.com)
  • Patients with advanced pancreatic cancer and weight loss have laboratory evidence of malnutrition (eg, low serum albumin or cholesterol level). (medscape.com)
  • Surgery is the only potentially curative treatment modality for early-stage pancreatic cancer. (medscape.com)
  • In adults, almost 90% are pancreatic cancer and a few are benign. (wikipedia.org)
  • After diagnosis and proper staging of pancreatic cancer, candidacy for surgical resection is then assessed. (wikipedia.org)
  • In the metastatic pancreatic cancer patient who had previously achieved a confirmed partial response, tumor reduction of both target lesions continued. (tmcnet.com)
  • Pancreatic cancer is the fourth leading cause of cancer-related death in the USA and Europe [ 1 ], and it is expected to overtake lung carcinoma as the second leading cause by 2030 [ 2 ]. (hindawi.com)
  • The most frequent type of pancreatic cancer is pancreatic ductal adenocarcinoma (PDAC), which accounts for up to 90% of pancreatic adenocarcinoma cases [ 3 ]. (hindawi.com)
  • The insidious and nonspecific symptoms of the disease make it difficult to diagnose, and cases of pancreatic cancer that can be definitively diagnosed are usually already in advanced stages. (hindawi.com)
  • In addition, a growing number of clinical cases have found that pancreatic cancer exhibits significant resistance to traditional treatment options, including chemotherapy, radiation, and immunotherapy [ 6 , 7 ]. (hindawi.com)
  • Pancreatic ductal adenocarcinoma (PDAC) is the fourth most common cause of cancer related death. (biomedcentral.com)
  • We developed a high-throughput 3D cell culture drug screening system for pancreatic cancer, which displays a strongly increased chemoresistance. (biomedcentral.com)
  • Pancreatic ductal adenocarcinoma (PDAC), which constitutes 90% of pancreatic cancers, is the fourth leading cause of cancer-related deaths in the world. (lu.se)
  • Despite advances in the efficacy and specificity of cancer treatments over the last decade, pancreatic cancer remains one of the leading causes of death worldwide. (cancer.gov)
  • Tests on human cervical carcinoma cells HeLa, squamous cell carcinoma WHCO5 and normal equine lung cell lines demonstrated that NSC631570 is selectively toxic against cancer cells. (ukrin.com)
  • Other cancers, including melanoma, breast cancer, and colon cancer, have been reported in RABL3 mutation-carrying individuals, with or without PDAC (Nissim et al. (nih.gov)
  • Pancreatic Cancer: Changing Epidemiology and New Approaches to Risk Assessment, Early Detection, and Prevention. (nih.gov)
  • ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility: summary and recommendations. (nih.gov)
  • Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death in developed countries [ 1 ], and it is expected to become the second leading cause of cancer death in 2030 [ 2 ]. (oncotarget.com)
  • Moreover, we examined roles of RV and AC using human pancreatic cancer cell lines (PANC-1 and MIAPaca-2) in vitro. (coxsignaling.com)
  • BRCA), ataxia telangiectasia mutated gene (ATM), or PALB2 screened for pancreatic cancer. (centerwatch.com)
  • To explore knowledge, attitudes, and anxiety related to pancreatic cancer screening at annual intervals in all study participants. (centerwatch.com)
  • Chemoembolization (CE) for other indications including palliative treatment of liver metastases from other non-neuroendocrine primaries (e.g., breast cancer, cervical cancer, colon cancer, esophageal cancer, melanoma, rhabdomyosarcoma, or unknown primaries) and CE of the pancreas for pancreatic cancer. (aetna.com)
  • Intra-hepatic microspheres for metastases from esophageal cancer, gallbladder cancer, uveal melanom a, liver metastases of pancreatic adenocarcinoma, and other indications not listed above. (aetna.com)
  • Her work is supported by the Pancreatic Cancer Research Fund (https://www.pcrf.org.uk), Science Foundation Ireland, through the Precision Oncology Ireland Consortium and the EU Horizon 2020 Marie Sklodowska-Curie Programme. (tcd.ie)
  • Patients and Methods Screening outcomes were collected from three European centers that conduct prospective screening in high-risk groups including families with clustering of PDAC (familial pancreatic cancer [FPC]) or families with a gene defect that predisposes to PDAC. (medscape.com)
Prognosis4
Intraductal3
  • The majority of pancreatic carcinomas are pancreatic ductal adenocarcinomas (PDAC), and the presence of non-invasive pancreatic intraepithelial neoplasia or intraductal papillary mucinous neoplasm, as an associated lesion, is considered important. (naramed-u.ac.jp)
  • These results suggest that MUC1 and TJP2, the putative target molecules of miR-345, are critical in maintaining the invasive potential of pancreatic carcinoma cells, and regulating their expression may prevent the progression of non-invasive pancreatic intraductal lesions to invasive carcinomas. (naramed-u.ac.jp)
  • I. To determine the rates of high-grade pancreatic neoplasia precursors (intraductal papillary mucinous neoplasm (IPMN)-high-grade dysplasia (HGD)) and pancreatic intraepithelial neoplasia-3 [PanIN-3]) and pancreatic ductal adenocarcinoma (PDAC) among all study participants. (centerwatch.com)
Neoplasia2
  • The knock-in p53 heterozygous and homozygous mice KPF develop the spectrum of pathologic changes seen cheats for counter strike global offensive human PDAC, including acinar to ductal metaplasia ADM, pancreatic intraepithelial neoplasia PanIN and invasive ductal carcinoma, with script bunny hop crossfire survival times of 4. (alchashop.com)
  • Gastrointestinal and pancreatobiliary pathology, with major emphasis on GI and pancreatic neoplasia, inflammatory bowel disease, biodesign innovation, and the application of machine learning to digital pathology. (stanford.edu)
Squamous cell carc1
Acinar5
  • Following PDACs, acinar cell carcinomas account for 5% of exocrine pancreatic cancers and can be "functioning", and overproduce certain molecules that can lead to some of the signs and symptoms that are often encountered in pancreatic cancers. (wikipedia.org)
  • Phylo-epigenetic and cell-type signature features derived from alpha, beta, acinar, and ductal adult cells suggest an exocrine cell of origin for PanNECs, thus separating them in cell lineage from other PanNENs of endocrine origin. (biomedcentral.com)
  • PanNECs can occur with admixed components of other carcinoma types of non-neuroendocrine origin, this can be either ductal adenocarcinoma (PDAC) or acinar cell carcinoma (ACC). (biomedcentral.com)
  • PDACs have been shown to originate from normal ductal or acinar cells [ 20 , 21 ], while G1 and G2 PanNETs have been shown to originate from endocrine cells of the pancreas [ 22 , 23 , 24 ]. (biomedcentral.com)
  • While SOX9 is absent in committed endocrine precursors, it is an important player in pancreatic ductal and centro-acinar cell development but not in adult acinar cells [ 36 , 37 ]. (biomedcentral.com)
Lesions3
  • In 1937, Brunschwig extended the indications for pancreaticoduodenectomy by performing the operation for pancreatic head lesions. (medscape.com)
  • These microscopic hyperplastic or grossly papillomatous lesions exhibit varying degrees of morphological atypia and may develop into invasive carcinomas. (naramed-u.ac.jp)
  • Surveillance of these high-risk groups may lead to early detection of PDAC or detection of precursor lesions (PRLs), allowing curative surgical treatment. (medscape.com)
Neuroendocrine tumor2
  • Advanced pheochromocytoma/paraganglioma (PPGL) or pancreatic neuroendocrine tumor (pNET). (medscape.com)
  • Two individuals (0.9%) in the FPC cohort had a pancreatic tumor, including one advanced PDAC and one early grade 2 neuroendocrine tumor. (medscape.com)
Patients10
  • These unique microscopic features and genetic markers are what allow for proper diagnosis and treatments in patients with pancreatic cancers. (wikipedia.org)
  • This resistance makes surgery the best option for pancreatic adenocarcinoma (PAAD) treatment, and for 10-20% of patients who undergo surgery, the 5-year survival rate is still only 15-25% [ 8 ]. (hindawi.com)
  • This is a Phase II, open-label, multi-center study to determine the efficacy and safety of MEDI4736 evaluated as single agent or in combination with tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) whose disease has progressed on fluoropyrimidine containing or gemcitabine-containing first-line chemotherapy.This study will consist of Part A, lead-in, as well as a possible expansion Part B. (astrazenecaclinicaltrials.com)
  • METHODS: Patients with PDAC submitted to staging laparoscopy either immediately before pancreatectomy or as a separate procedure between January 2010 and December 2016 were included. (bvsalud.org)
  • The clinicopathological parameters and molecular alterations were analyzed based on survival indices and using a validation/comparative cohort of 480 conventional PDAC patients. (univr.it)
  • Results: The study included 40 patients with 20 nonneoplastic specimens and 19 PDAC specimens (1 case of neuroendocrine carcinoma was omitted). (elsevierpure.com)
  • In June 2022, BioNTech SE announced initial data from an ongoing investigator-initiated first-in-human Phase 1 study evaluating the safety and tolerability of the mRNA-based individualized neoantigen-specific immunotherapy (iNeST) autogene cevumeran (also known as BNT122, RO7198457) in combination with anti-PD-L1 immune checkpoint inhibitor atezolizumab and chemotherapy in patients with resected pancreatic ductal adenocarcinoma (PDAC). (lucknownewsflash.in)
  • Abdominal pain is an important symptom in most patients with pancreatic ductal adenocarcinoma (PDAC). (bvsalud.org)
  • Hereditary factors play a role in the development of PDAC in 3% to 5% of all patients. (medscape.com)
  • Currently, surgical resection is the only potentially curative treatment for PDAC, but in approximately 80% of symptomatic patients, the tumor is already unresectable at the time of diagnosis. (medscape.com)
Type of pancreatic3
  • Each different type of pancreatic tumor has a different appearance when examined under a microscope. (wikipedia.org)
  • The most common type of pancreatic tumor is pancreatic adenocarcinoma, which accounts near 90% of all pancreas cancers. (wikipedia.org)
  • The most common type of pancreatic tumor, Pancreatic Ductal Adenocarcinoma (PDAC), has distinctly poor patient outcomes due to its. (cancer.gov)
Pancreas2
20191
  • 2019). For background, phenotypic description, and a discussion of genetic heterogeneity of pancreatic carcinoma, see 260350. (nih.gov)
Invasive1
  • The IPMNs were finally diagnosed as low-grade dysplasia (LDA, n = 42), high-grade dysplasia (HAD, n = 19), and invasive carcinoma (IPMC, n = 30). (biomedcentral.com)
Metastasis1
  • In a PDAC tissue, desmoplastic stroma generally constitutes 70~90% of total tumor volume and is closely associated with rapid tumor growth, immunosuppression, metastasis, and therapeutic resistance. (nhri.org.tw)
20221
  • DelveInsight's, "Pancreatic Ductal Adenocarcinoma Pipeline Insight, 2022," report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Pancreatic Ductal Adenocarcinoma pipeline landscape. (lucknownewsflash.in)
Adenocarcinomas1
  • Different subtypes of exocrine adenocarcinomas exist, with the most common being pancreatic ductal adenocarcinoma (PDAC). (wikipedia.org)
Therapies4
  • In this review, we summarize currently available therapies and clinical trials, directed towards a plethora of pathways and components dysregulated during PDAC carcinogenesis. (lu.se)
  • This study provides new insights for the development of novel molecular targeted therapies for pancreatic carcinomas. (naramed-u.ac.jp)
  • DelveInsight's Pancreatic Ductal Adenocarcinoma Pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Pancreatic Ductal Adenocarcinoma. (lucknownewsflash.in)
  • The Pancreatic Ductal Adenocarcinoma pipeline therapies under development are focused on novel approaches to treat/improve Pancreatic Ductal Adenocarcinoma. (lucknownewsflash.in)
Cancers1
  • Due to the broad heterogeneity of genetic mutations and dense stromal environment, PDAC belongs to one of the most chemoresistant cancers. (lu.se)
Vitro2
  • The Titanium Surface Modulates the Expression of Beta-Catenin and DLX5 Genes in Pancreatic Ductal Carcinoma in Vitro. (unina.it)
  • In this study, we investigated whether mucin-1 (MUC1) is involved in the progression of pancreatic carcinoma and examined the mechanisms by which microRNAs regulate MUC1 expression in vitro. (naramed-u.ac.jp)
Cell proliferation3
  • PDAC cell lines transfected with an miR-345 precursor suppressed the expression of MUC1, and reduced cell proliferation and invasion. (naramed-u.ac.jp)
  • Ki-67 labeling indices and the level of lipid peroxidation in normal pancreatic ducts were decreased in both RV and AC groups, therefore, the mechanism of tumor suppression appears to involve regulation of cell proliferation and oxidative stress. (coxsignaling.com)
  • Conclusion: RV and AC suppressed hamster pancreatic ductal carcinogenesis through regulation of cell proliferation and oxidative stress although correlation between Fulvestrant mw adiponectin and pancreatic carcinogenesis was not clear. (coxsignaling.com)
Carcinogenesis1
  • This study aimed to elucidate effects of adiponectin on pancreatic carcinogenesis in animal model. (coxsignaling.com)
Computed tomography1
  • Pancreatic-protocol computed tomography (CT) with thin collimation will detect anatomic contraindications for surgical resection. (medscape.com)
Tissue1
  • Pancreatic ductal adenocarcinoma (PDAC) specimens were obtained via endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) and non-neoplastic tissue was obtained via surgery. (elsevierpure.com)
Resection3
  • In 1946, Waugh and Clagett described a formal en-bloc resection of the gallbladder with the common bile duct (CBD), gastric antrum, duodenum, and pancreatic head performed as a one-stage procedure, which we recognize today as the classic pancreaticoduodenectomy. (medscape.com)
  • Although innumerable details of pancreaticoduodenectomy yield to continued innovation, a comprehensive discussion of intraoperative variants (ie, duct to mucosa vs invagination of the pancreaticojejunal anastomosis, diverse approaches to vein resection and reconstructions, nuances of each enteric anastomosis, and modifications of Roux-en-Y reconstructions, to name a few) is beyond the scope of this article. (medscape.com)
  • Surgical resection of localized PDAC is the only treatment that can provide prolonged survival. (oncotarget.com)
Clinical2
  • It covers the Pancreatic Ductal Adenocarcinoma pipeline drug profiles, including Pancreatic Ductal Adenocarcinoma clinical trials and nonclinical stage products. (lucknownewsflash.in)
  • In the Pancreatic Ductal Adenocarcinoma Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, Pancreatic Ductal Adenocarcinoma clinical trial studies, Pancreatic Ductal Adenocarcinoma NDA approvals (if any), and product development activities comprising the technology, Pancreatic Ductal Adenocarcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details. (lucknownewsflash.in)
Tumor suppressor1
  • These results define CYB5A as a novel prognostic factor for PDAC that exerts its tumor-suppressor function through autophagy induction and TRAF6 modulation. (nih.gov)